SPRO Spero Therapeutics

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update, on March 27, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET.  

To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10196669, or click on this and request a return call. The Call me™ passcode is 9270590. The audio webcast can be accessed live on this or on the “Events and Presentations” page under the “Investor Relations” tab of the Spero Corporate Website at . The archived webcast will also be available on Spero’s website for 30 days following the call.

About Spero Therapeutics

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. For more information, visit

Investor Relations Contact:

Shai Biran, PhD

Spero Therapeutics

Media Inquiries:



EN
18/03/2025

Underlying

SPROSpero Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spero Therapeutics

 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics Announces First Quarter 2025 Operating Results and ...

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), on track to be completed in Q2 2025Existing cash, together with earned development milestones from GSK, provide runway to fund operating expenses and capital expenditures into Q2 2026 CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on iden...

May 13, 2025 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics to Report First Quarter 2025 Financial Results and ...

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsS...

May 5, 2025 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Exe...

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero’s 2025 annual meeting of stockholders. Since January 2025, Ms. Ra...

April 28, 2025 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operati...

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analysis of full data set from the Phase 2 study of SPR720 for treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) and determine next steps for the programSPR206, a Phase 2 ready program for hospital and ventilator acquired bacterial pneumonia (HABP/VABP), discontinued fol...

March 27, 2025 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financi...

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025 CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update, on March 27, 2025. Management w...

March 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch